Frits van Alphen, a pharma veteran, has joined Inositec AG as chief medical officer to oversee development of the company’s small molecule drugs to treat calcification disorders. Dr van Alphen joins from Roche where he headed the operational excellence team. He was previously CMO at Vifor Pharma AG and before that, head of medical affairs in Europe for Novartis.
Dr van Alphen earned his medical degree at Leiden University in the Netherlands.
Inositec announced the appointment on 18 January 2018.
Copyright 2018 Evernow Publishing Ltd